The company has submitted the application on the basis of positive results which it has witnessed form preclinical studies.
The studies showed Alliqua’s hydrogel based patch technology successfully delivering an active pharmaceutical ingredient (API) with efficacy from both a time of onset and duration perspective.
The new patent application covers several specific characteristics of the technology and formulations, which according to the company is unique to its platform.
Alliqua CEO Matthew Harriton said filing the patent on these important innovations is a significant step towards securing intellectual property position and moving forward with potential strategic relationships and commercialization.
"We anticipate adding to the breadth of these filings as we further study the technology and its applications," Harriton said.